TRANSGENE AND THE INTERNATIONAL AIDS VACCINE INITIATIVE (IAVI) SIGN MANUFACTURING AGREEMENT

A A

Transgene today announced its agreement with the International AIDS Vaccine Initiative (IAVI) for process development and manufacturing of an AIDS vaccine candidate for use in clinical trials. The vaccine candidate uses the Adenovirus-35 vector technology and expresses HIV-1 antigens. Building on Transgene's viral vectors manufacturing processes and long experience in the field, two vaccine batches and related pharmaceutical intermediates will be produced in Transgene's manufacturing facility located near Strasbourg, France.

Euronext (http://www.euronext.com/news/companypressrelease/0,4616,1700631_11894_690597479,00.html)